Does Mesenchymal Stromal Cell Count in Pre-autologous Hematopoietic Stem Cell Transplant Peripheral Blood and Apheresis Product Predict for Infectious Complications in the Post-transplant Period?
Engraftment
Infections
Mesenchymal stromal cells
Mucositis
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
22
07
2020
accepted:
05
11
2020
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
17
7
2021
Statut:
ppublish
Résumé
Mesenchymal stromal cells (MSC) have gained attention in the recent past considering their multipotentiality and organ-healing properties. Exogenous administration of MSC in the pre-hematopoietic stem cell transplant (HSCT) setting has been reported to enhance engraftment, heal graft-vs-host disease and increase infections in the post-HSCT period. In this study, we aimed to determine the effect of endogenous pre-HSCT MSC on the post-HSCT infectious complications in patients undergoing autologous-HSCT. The study included patients undergoing autologous-HSCT (n = 25; multiple myeloma-20, lymphoma-5). MSC were analyzed and quantified by flow cytometry in the peripheral blood (PB) at baseline, and in both PB and apheresis product (AP) following mobilization with growth factors. Pre-HSCT MSC (PB/AP) were correlated with the post-HSCT duration of febrile neutropenia and duration of antimicrobial drugs using Pearson's correlation co-efficient, and with the mucositis grade using Spearman's rank correlation. Pre-HSCT MSC (baseline and post-mobilization) correlated positively with the longer duration of febrile neutropenia and duration of antimicrobials used in the post-HSCT period (
Identifiants
pubmed: 34267471
doi: 10.1007/s12288-020-01379-5
pii: 1379
pmc: PMC8239070
doi:
Types de publication
Journal Article
Langues
eng
Pagination
484-488Informations de copyright
© Indian Society of Hematology and Blood Transfusion 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflicts of interests.
Références
Hum Cell. 2014 Oct;27(4):137-50
pubmed: 24903975
Bone Marrow Transplant. 1997 Aug;20(4):265-71
pubmed: 9285540
Leukemia. 2008 Mar;22(3):593-9
pubmed: 18185520
Br J Haematol. 2020 May;189(4):772-776
pubmed: 32011732
Int J Hematol. 2012 Dec;96(6):822-4
pubmed: 23143687
Blood. 2007 Oct 1;110(7):2764-7
pubmed: 17638847
Leukemia. 2014 Oct;28(10):1941-8
pubmed: 24762460
Strahlenther Onkol. 2014 Apr;190(4):399-404
pubmed: 24452815
Biol Blood Marrow Transplant. 2012 Apr;18(4):557-64
pubmed: 21820393
Bone Marrow Transplant. 2006 May;37(10):967-76
pubmed: 16670702
Eur J Haematol. 2012 Sep;89(3):220-7
pubmed: 22765507
J Hematother. 1997 Oct;6(5):447-55
pubmed: 9368181
Cytotherapy. 2016 Feb;18(2):172-85
pubmed: 26794711
Leukemia. 2007 Aug;21(8):1733-8
pubmed: 17541394
J Cell Biochem. 1997 Feb;64(2):278-94
pubmed: 9027588
Stem Cell Res Ther. 2015 Sep 07;6:165
pubmed: 26345192
Arthritis Res. 2000;2(6):477-88
pubmed: 11056678
Cell Death Differ. 2014 Feb;21(2):216-25
pubmed: 24185619
Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47
pubmed: 20109568
Blood Rev. 2006 May;20(3):161-71
pubmed: 16364518